Summary
The HMG-CoA reductase inhibitor, lovastatin, is known to induce asymptomatic liver dysfunction in a few patients. We report the case of an adult who suffered from clinical hepatitis three months after the onset of lovastatin administration. Manifestations included asthenia, jaundice, and increased aminotransferase and alkaline phosphatase activities. Histologic examination showed centrilobular necrosis, centrilobular cholestasis, and infiltrates with mononuclear and polymorphonuclear cells, including eosinophils. Withdrawal of lovastatin was followed by complete normalization of liver tests within two months.
Similar content being viewed by others
References
Grundy SM: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24–31, 1988
Oates JA, Wood AJ: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24–33, 1988
Stein EA, Lamkin GE, Bewley DZ: Lovastatin alone and in combination for treatment of primary hypercholesterolemia. Prog Clin Biol 255:281–293, 1988
Lovastatin Study Groups I through IV: Lovastatin 5-year safety and efficacy study. Arch Intern Med 153:1079–1087, 1993
McQueen MJ: Cholestatic jaundice associated with lovastatin therapy. Can Med Assoc J 142:841–842, 1990
Raveh D, Israeli A, Arnon R, Eisenberg S: Lovastatin-induced hepatitis. Isr J Med Sci 28:101–102, 1992
Mantell G, Burke MT, Staggers J: Extended clinical safety profile of lovastatin. Am J Cardiol 66:11B-15B, 1990
Sarachek NS, London RL, Matulewicz TJ: Diltiazem and granulomatous hepatitis. Gastroenterology 88:1260–1262, 1985
Asorey A, Garcia-Alegria JJ, Garcia-Garcia I, Jimenez LC, Blasquez ML: Cholestatic hepatitis from diltiazem. Eur J Intern Med 2:245–246, 1992
Ballare M, Campani M, Catania E, Bordin G, Zaccala G, Monteverde A: Acute cholestatic hepatitis during simvastatin administration. Recenti Prog Med 82:233–235, 1991
Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y, Wakasugi T, et al: Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med 305:478–482, 1981
Komai T, Kawai K, Tokui T, Tokui Y, Kuroiwa C, Shigehara E, et al: Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur J Drug Metab Pharmacokinet 17:103–113, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grimbert, S., Pessayre, D., Degott, C. et al. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Digest Dis Sci 39, 2032–2033 (1994). https://doi.org/10.1007/BF02088142
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02088142